Opiant Pharmaceuticals Inc (NASDAQ:OPNT) major shareholder Geoffrey Wolf sold 2,570 shares of the business’s stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $30.40, for a total value of $78,128.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) traded down $0.51 during midday trading on Tuesday, hitting $29.50. The stock had a trading volume of 72,500 shares, compared to its average volume of 35,431. The company has a market capitalization of $62.06, a price-to-earnings ratio of 71.45 and a beta of -2.33. Opiant Pharmaceuticals Inc has a 1 year low of $5.00 and a 1 year high of $51.90.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings data on Monday, December 4th. The technology company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($1.58). The business had revenue of $0.02 million during the quarter. Opiant Pharmaceuticals had a return on equity of 42.44% and a net margin of 8.93%. research analysts forecast that Opiant Pharmaceuticals Inc will post -5.12 earnings per share for the current year.

Several analysts have issued reports on OPNT shares. ValuEngine raised Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, September 6th. TheStreet raised Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday, October 16th.

TRADEMARK VIOLATION WARNING: “Opiant Pharmaceuticals Inc (OPNT) Major Shareholder Geoffrey Wolf Sells 2,570 Shares” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/12/12/opiant-pharmaceuticals-inc-opnt-major-shareholder-geoffrey-wolf-sells-2570-shares.html.

Opiant Pharmaceuticals Company Profile

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.